Next Article in Journal
Clinical Utility and Limitation of Diagnostic Ability for Different Degrees of Dysplasia of Intraductal Papillary Mucinous Neoplasms of the Pancreas Using 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
Previous Article in Journal
Generation of Antibody-Drug Conjugate Resistant Models
Previous Article in Special Issue
New Trends in Esophageal Cancer Management
Review

Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?

1
Division of Oncology, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria
2
Comprehensive Cancer Center Vienna, 1090 Vienna, Austria
*
Author to whom correspondence should be addressed.
Academic Editors: Caroline Gronnier and Denis Collet
Cancers 2021, 13(18), 4632; https://doi.org/10.3390/cancers13184632
Received: 23 August 2021 / Revised: 10 September 2021 / Accepted: 13 September 2021 / Published: 15 September 2021
(This article belongs to the Special Issue New Trends in Esophageal Cancer Management)
Recent studies concerning immunotherapeutic agents are bound to revolutionize therapeutic strategies for esophageal cancer patients. This review aims to summarize novel clinical data and provide a critical view of potential restrictions for the implementation of immunotherapy for unselected patient populations.
The prognosis of advanced esophageal cancer is dismal, and treatment options are limited. Since the first promising data on second-line treatment with checkpoint inhibitors in esophageal cancer patients were published, immunotherapy was surmised to change the face of modern cancer treatment. Recently, several studies have found this to be true, as the checkpoint inhibitors nivolumab and pembrolizumab have achieved revolutionary response rates in advanced as well as resectable settings in esophageal cancer patients. Although the current results of large clinical trials promise high efficacy with tolerable toxicity, desirable survival rates, and sustained quality of life, some concerns remain. This review aims to summarize the novel clinical data on immunotherapeutic agents for esophageal cancer and provide a critical view of potential restrictions for the implementation of these therapies for unselected patient populations. View Full-Text
Keywords: esophageal cancer; esophageal adenocarcinoma; esophageal squamous cell carcinoma; immunotherapy esophageal cancer; esophageal adenocarcinoma; esophageal squamous cell carcinoma; immunotherapy
MDPI and ACS Style

Puhr, H.C.; Preusser, M.; Ilhan-Mutlu, A. Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021? Cancers 2021, 13, 4632. https://doi.org/10.3390/cancers13184632

AMA Style

Puhr HC, Preusser M, Ilhan-Mutlu A. Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021? Cancers. 2021; 13(18):4632. https://doi.org/10.3390/cancers13184632

Chicago/Turabian Style

Puhr, Hannah C., Matthias Preusser, and Aysegül Ilhan-Mutlu. 2021. "Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?" Cancers 13, no. 18: 4632. https://doi.org/10.3390/cancers13184632

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop